Jessie Ng, PhD, MS
Title | Research Faculty PhD |
---|
Institution | Children's Mercy Kansas City |
---|
Department | Pediatrics |
---|
Address | 2401 Gillham Rd Kansas City MO 64108
|
---|
vCard | Download vCard |
---|
|
|
|
Title | Assistant Professor of Pediatrics |
---|
Institution | University of Missouri-Kansas City |
---|
Department | Pediatrics |
---|
|
---|
Title | Research Assistant Professor of Cancer Biology |
---|
Institution | University of Kansas Medical Center |
---|
Department | Cancer Biology |
---|
|
---|
|
Biography St Jude Children’s Research Hospital, Memphis, TN, USA | Fellowship | | Developmental Neurobiology | Erasmus Medical Center, Erasmus University of Rotterdam, Rotterdam, The Netherlands | Fellowship | | Cell Biology and Genetics | Erasmus Medical Center Erasmus University of Rotterdam, Rotterdam, The Netherlands | PhD | | Cell Biology and Genetics | Leiden University, Leiden, The Netherlands | MS | | Medical Biology, Molecular Cell Biology, and Molecular Genetics & Developmental Genetics | Institute of Higher Professional Education of Engineering & Technology, Delft & Rotterdam, The Netherlands | BS | | Medical Biotechnology and Clinical Genetics |
2004 - 2006 | LIMA International Award for Excellence in Pediatric Brain Tumor Research, Children Brain Tumor Foundation (CBTF) | 2008 | Most outstanding presentation in the clinical/translational track, The Children’s Hospital of Philadelphia | 2008 | Scholar-in-Training Award, American Association for Cancer Research (AACR) | 2008 | AACR-WICR Brigid G. Leventhal Scholar in Cancer Research Award, American Association for Cancer Research (AACR) |
Overview Research Dr. Jessie Ng is working to develop better treatments for the aggressive brain tumors medulloblastoma (MB) and atypical teratoid rhabdoid tumor (AT/RT). Over the past several years, Dr. Ng and coworkers in Dr. Curran’s lab helped develop a new approach to the treatment of MB using Hedgehog (Hh) pathway inhibitors. The lab conducted molecular gene expression studies that identified four major subtypes of MB tumors and developed a mouse model (Ptc1/p53) for high-incidence, early-onset Hh subtype MB. Using this spontaneous central nervous system (CNS) mouse model, they demonstrated that oral delivery of small molecule inhibitors of Smoothened (Smo), called GDC-0449 or vismodegib, eliminated even large spontaneous brain tumors in mice. They worked with Curis Inc., and later Genentech Inc., to demonstrate proof-of-concept of the use of Hh inhibitors in cancer. This work led to successful Phase I and II clinical trials of Smo inhibitors in pediatric and adult MB that recapitulated all the major findings obtained in mice. Because of these efforts, the first Smo inhibitor (vismodegib) was approved for treatment of advanced basal cell carcinoma in 2012. The next step is to focus on targeting drug-resistant brain tumors. Dr. Ng will use in vitro high-throughput drug screening as well as noninvasive imaging approaches (such as MRI and CT), drug delivery therapies and next-generation sequencing. The ultimate goal of the research is to develop new drugs for clinical trials in pediatric brain cancer. Dr. Ng’s research is also investigating the role of INI1 (Integrase Interactor 1), also known as SNF5 or SMARCB1. SNF5 is a key component of the SWI/SNF (switch/sucrose nonfermentable) chromatin remodeling tumor suppressor complex, which is an ATP-dependent nucleosome-remodeling complex that regulates gene transcription in CNS development and tumorigenesis, including the pediatric CNS tumor AT/RT. Dr. Ng has generated the first CNS mouse model for AT/RT, which is quite crucial because with this model they can now test potential drugs in vivo and investigate the cell of origin to understand the cancer biology of AT/RT.
(Jessie Ng)Jan 1, 2018 Children's Mercy Hospital Midwest Cancer Alliance Partner Advisory Board Funding Overcoming drug resistance in Hedgehog pathway medulloblastoma Role Description: To identify, understand, and overcome the mechanisms responsible for resistance to Hedgehog (Smoothened) inhibitors Role: PI |
Bibliography
-
Du F, Yuelling L, Lee EH, Wang Y, Liao S, Cheng Y, Zhang L, Zheng C, Peri S, Cai KQ, Ng JMY, Curran T, Li P, Yang ZJ. Leukotriene Synthesis Is Critical for Medulloblastoma Progression. Clin Cancer Res. 2019 11 01; 25(21):6475-6486. PMID: 31300449.
-
Gordon RE, Zhang L, Peri S, Kuo YM, Du F, Egleston BL, Ng JMY, Andrews AJ, Astsaturov I, Curran T, Yang ZJ. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma. Clin Cancer Res. 2018 03 15; 24(6):1375-1388. PMID: 29437795.
-
Liu Y, Yuelling LW, Wang Y, Du F, Gordon RE, O'Brien JA, Ng JMY, Robins S, Lee EH, Liu H, Curran T, Yang ZJ. Astrocytes Promote Medulloblastoma Progression through Hedgehog Secretion. Cancer Res. 2017 12 01; 77(23):6692-6703. PMID: 28986380.
-
Li P, Lee EH, Du F, Gordon RE, Yuelling LW, Liu Y, Ng JM, Zhang H, Wu J, Korshunov A, Pfister SM, Curran T, Yang ZJ. Nestin Mediates Hedgehog Pathway Tumorigenesis. Cancer Res. 2016 09 15; 76(18):5573-83. PMID: 27496710.
-
Melo FM, Couto PP, Bale AE, Bastos-Rodrigues L, Passos FM, Lisboa RG, Ng JM, Curran T, Dias EP, Friedman E, De Marco L. Whole-exome identifies RXRG and TH germline variants in familial isolated prolactinoma. Cancer Genet. 2016 06; 209(6):251-7. PMID: 27245436.
-
Ng JM, Martinez D, Marsh ED, Zhang Z, Rappaport E, Santi M, Curran T. Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53. Cancer Res. 2015 Nov 01; 75(21):4629-39. PMID: 26363008.
-
Gurung B, Feng Z, Iwamoto DV, Thiel A, Jin G, Fan CM, Ng JM, Curran T, Hua X. Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Res. 2013 Apr 15; 73(8):2650-8. PMID: 23580576.
-
Wang Y, Davidow L, Arvanites AC, Blanchard J, Lam K, Xu K, Oza V, Yoo JW, Ng JM, Curran T, Rubin LL, McMahon AP. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chem Biol. 2012 Aug 24; 19(8):972-82. PMID: 22921064.
-
Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer. 2011 May 26; 11(7):493-501. PMID: 21614026.
-
Brechbiel JL, Ng JM, Curran T. PTHrP treatment fails to rescue bone defects caused by Hedgehog pathway inhibition in young mice. Toxicol Pathol. 2011 Apr; 39(3):478-85. PMID: 21411723.
-
Hoogstraten D, Bergink S, Ng JM, Verbiest VH, Luijsterburg MS, Geverts B, Raams A, Dinant C, Hoeijmakers JH, Vermeulen W, Houtsmuller AB. Versatile DNA damage detection by the global genome nucleotide excision repair protein XPC. J Cell Sci. 2008 Sep 01; 121(Pt 17):2850-9. PMID: 18682493.
-
Kimura H, Ng JM, Curran T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell. 2008 Mar; 13(3):249-60. PMID: 18328428.
-
Giglia-Mari G, Miquel C, Theil AF, Mari PO, Hoogstraten D, Ng JM, Dinant C, Hoeijmakers JH, Vermeulen W. Dynamic interaction of TTDA with TFIIH is stabilized by nucleotide excision repair in living cells. PLoS Biol. 2006 Jun; 4(6):e156. PMID: 16669699.
-
Okuda Y, Nishi R, Ng JM, Vermeulen W, van der Horst GT, Mori T, Hoeijmakers JH, Hanaoka F, Sugasawa K. Relative levels of the two mammalian Rad23 homologs determine composition and stability of the xeroderma pigmentosum group C protein complex. DNA Repair (Amst). 2004 Oct 05; 3(10):1285-95. PMID: 15336624.
-
Ng JM, Vermeulen W, van der Horst GT, Bergink S, Sugasawa K, Vrieling H, Hoeijmakers JH. A novel regulation mechanism of DNA repair by damage-induced and RAD23-dependent stabilization of xeroderma pigmentosum group C protein. Genes Dev. 2003 Jul 01; 17(13):1630-45. PMID: 12815074.
-
Jaspers NG, Raams A, Kelner MJ, Ng JM, Yamashita YM, Takeda S, McMorris TC, Hoeijmakers JH. Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair (Amst). 2002 Dec 05; 1(12):1027-38. PMID: 12531012.
-
Ng JM, Vrieling H, Sugasawa K, Ooms MP, Grootegoed JA, Vreeburg JT, Visser P, Beems RB, Gorgels TG, Hanaoka F, Hoeijmakers JH, van der Horst GT. Developmental defects and male sterility in mice lacking the ubiquitin-like DNA repair gene mHR23B. Mol Cell Biol. 2002 Feb; 22(4):1233-45. PMID: 11809813.
-
Neuteboom LW, Ng JM, Kuyper M, Clijdesdale OR, Hooykaas PJ, van der Zaal BJ. Isolation and characterization of cDNA clones corresponding with mRNAs that accumulate during auxin-induced lateral root formation. Plant Mol Biol. 1999 Jan; 39(2):273-87. PMID: 10080694.
-
Sugasawa K, Ng JM, Masutani C, Iwai S, van der Spek PJ, Eker AP, Hanaoka F, Bootsma D, Hoeijmakers JH. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell. 1998 Aug; 2(2):223-32. PMID: 9734359.
-
Sugasawa K, Ng JM, Masutani C, Maekawa T, Uchida A, van der Spek PJ, Eker AP, Rademakers S, Visser C, Aboussekhra A, Wood RD, Hanaoka F, Bootsma D, Hoeijmakers JH. Two human homologs of Rad23 are functionally interchangeable in complex formation and stimulation of XPC repair activity. Mol Cell Biol. 1997 Dec; 17(12):6924-31. PMID: 9372924.
-
Chiurazzi P, de Graaff E, Ng J, Verkerk AJ, Wolfson S, Fisch GS, Kozak L, Neri G, Oostra BA. No apparent involvement of the FMR1 gene in five patients with phenotypic manifestations of the fragile X syndrome. Am J Med Genet. 1994 Jul 15; 51(4):309-14. PMID: 7942992.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
1994 | 1 | 1997 | 1 | 1998 | 1 | 1999 | 1 | 2002 | 2 | 2003 | 1 | 2004 | 1 | 2006 | 1 | 2008 | 2 | 2011 | 2 | 2012 | 1 | 2013 | 1 | 2015 | 1 | 2016 | 2 | 2017 | 1 | 2018 | 1 | 2019 | 1 |
To return to the timeline, click here.
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|